INP106

INP106 is a preclinical-stage drug candidate developed by Impel Pharmaceuticals for the treatment of pain. The asset utilizes the company's proprietary Precision Olfactory Delivery (POD) technology, a handheld device designed to deliver small molecule formulations to the vascular-rich upper nasal cavity. This delivery method aims to achieve rapid systemic absorption and potentially direct-to-brain transport, offering a non-invasive alternative to injections with a faster onset of action than oral medications. As of the last available pipeline updates, the specific active pharmaceutical ingredient for INP106 remained undisclosed.